Page last updated: 2024-08-21

arsenic trioxide and Leukemia, Myeloid, Acute

arsenic trioxide has been researched along with Leukemia, Myeloid, Acute in 92 studies

Research

Studies (92)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	20 (21.74)	29.6817
2010's	53 (57.61)	24.3611
2020's	19 (20.65)	2.80

Authors

Authors	Studies
Fang, M; Liao, C; Shen, D; Shen, H; Song, H; Tang, Y; Wang, Y; Zhang, J; Zhu, H	1
Buettner, R; Burnett, J; Ghoda, L; Hoang, DH; Kuo, YH; Marcucci, G; Nguyen, LXT; Pullarkat, V; Rosen, ST; Valerio, M; Zhang, B	1
Kumar, S; Tchounwou, PB	1
Herold, T; Hiddemann, W; Rausch, C; Spiekermann, K; von Bergwelt-Baildon, M	1
Sun, WD; Tong, XM; Wang, X; Wang, Y	1
Bai, LH; Jiang, YF; Li, J; Li, RJ; Peng, HL; Shen, JK; Yan, WZ	1
Liu, F; Wu, M; Wu, XP; Wu, ZH; Yuan, QQ; Zeng, YJ; Zhang, DL; Zhou, L	1
Ball, ED; Borthakur, G; Cai, Z; Chen, SN; Chu, XX; Du, X; Gao, SJ; Hao, JP; Hu, J; Huang, JY; Huang, RB; Jin, J; Kantarjian, HM; Li, J; Li, JH; Liu, HX; Liu, LP; Liu, YJ; Lu, Y; Luo, H; MacMahon, S; Mi, YC; Qin, YZ; Sanz, MA; Shen, SH; Su, Z; Such, E; Taussig, DC; Wang, HY; Wang, W; Wang, Y; Welch, JS; Wen, LJ; Xu, R; Yan, XJ; Yin, CC; You, MJ; Yu, L; Yu, YF; Yuan, HJ; Zhang, C; Zhang, JY; Zhang, LP; Zhang, XY; Zhang, ZL; Zhou, HS; Zhu, HH	1
Balasubramanian, P; David, E; Illangeswaran, RSS; Janet, NB; Jebanesan, DZP; Mathews, V; Rajamani, BM; Sivakumar, KK; Velayudhan, SR; Vidhyadharan, RT	1
Cao, P; Chen, J; Chen, X; Fang, J; Li, H; Li, L; Liu, H; Liu, M; Ma, X; Wang, F; Wu, H; Yuan, L; Zhang, Y; Zhao, Z; Zhou, X	1
Adès, L; de la Serna, J; Fenaux, P; Garrido, A; Ghiaur, G; Gil, C; Guerci-Bresler, A; Kayser, S; Lengfelder, E; Levis, MJ; Martínez-Cuadrón, D; Montesinos, P; Pigneux, A; Platzbecker, U; Raffoux, E; Rahmé, R; Salamero, O; Sanz, MA; Schlenk, RF; Sobas, M; Thomas, X; Tormo, M; Vey, N	1
Fan, Z; Huang, DP; Huang, LB; Li, Y; Liang, C; Luo, XQ; Peng, CJ; Tang, WY; Tang, YL; Wang, LN; Zhang, XL; Zheng, LM	1
Naoe, T	1
Fakhimahmadi, A; Ghavamzadeh, A; Haghi, A; Mohammadi Kian, M; Mohammadi, S; Moosavi, MA; Nikbakht, M; Rahmati, M; Salemi, M; Yousefi, H	1
Baakhlagh, S; Bashash, D; Ghaffari, SH; Kashani, B; Moradkhani, M; Mousavi, SA; Nasrollahzadeh, A; Yaghmaei, M; Zandi, Z	1
de Botton, S; DiNardo, CD; Fathi, AT; Levis, MJ; Montesinos, P; Stein, EM	1
DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA	1
Chu, X; Wei, Q; Zhang, Y	1
Annibali, O; Arcese, W; Castelli, R; Cicconi, L; Cristiano, A; Della Porta, M; Divona, M; Esteve, J; Fabiani, E; Falconi, G; Lazarevic, V; Lo-Coco, F; Montesinos, P; Nardozza, AM; Ottone, T; Rego, E; Rossi, M; Testi, AM; Venditti, A; Voso, MT	1
Angelini, DF; Battistini, L; Berardi, A; Castelli, G; Catalano, G; Cicconi, L; D'Angiò, A; Fioritoni, G; Graziani, G; Guerrera, G; Lo-Coco, F; Massai, L; Mastrangelo, D; Noguera, NI; Pasquini, L; Pelosi, E; Piras, E; Piredda, ML; Testa, U; Voso, MT	1
Chahardouli, B; Ghavamzadeh, A; Mohammadi Kian, M; Mohammadi, S; Nikbakht, M; Rostami, S; Tavallaei, M; Zahedpanah, M	1
Ding, SM; Kan, JY; Wang, Y; Xu, RR	1
Ahmadian, S; Ghaffari, SH; Ghavamzadeh, A; Mesbahi, Y; Tabatabaie, PS; Zekri, A	1
Castelli, G; Labbaye, C; Ottone, T; Pasquini, L; Pelosi, E; Quaranta, MT; Saulle, E; Spinello, I; Testa, U; Voso, MT	1
Abbaszade Dibavar, M; Amiri, S; Atashi, A; Rassaei, N; Soleimani, M	1
Chen, P; Chen, Y; Hou, D; Huang, H; Jin, Q; Wang, B; Wang, X; You, P; You, R; Zhan, W; Zou, H	1
Chen, J; Chen, L; Chen, M; He, Z; Huang, Y; Lu, Y; Wang, B; Wang, H; Wu, Y; Xiao, X; Yang, M	1
Fang, Z; Gong, T; Hong, L; Liu, D; Lu, R; Ma, J; Wang, Z; Zhang, M; Zhao, H	1
Cao, P; Chen, X; Liu, H; Liu, M; Ma, X; Nie, D; Teng, W; Tian, Y; Wang, F; Wang, T; Wang, W; Zhang, J; Zhang, Y	1
Aster, JC; Avigan, D; Bhasin, MK; Cheloni, G; Chen, M; Clohessy, JG; Galinsky, I; Guarnerio, J; Lane, AA; Lee, JD; Lo-Coco, F; Longo, L; Mendez, L; Menon, AV; Monteleone, E; Mugoni, V; Pandolfi, PP; Panella, R; Pozdnyakova, O; Stone, RM; Stroopinsky, D; Zamora, JC	1
Chen, L; Han, F; Qu, H; Ren, L; Yan, H; Yang, S	1
Baumann, H; Brady, MT; Ford, LA; Lee, KP; Miller, A; Minderman, H; Sait, SN; Wang, ES; Wetzler, M	1
Bae, JY; Kim, I; Kim, JW	1
Fan, RH; Mi, RH; Song, YP; Wei, XD; Xu, JX; Yin, QS	1
Cen, JN; Fu, CM; Hu, SY; Jiao, Y; Li, Z; Qi, XF; Qiu, HY; Wu, DP; Zhu, MQ	1
Chan, SM; Feng, W; Huang, M; Li, MX; Majeti, R; Mitchell, BS; Thomas, D	1
Mehta, SV; Shukla, SN; Vora, HH	1
Fujii, Y; Komatsu, T; Shigemi, H; Tanaka, Y; Yamauchi, T	1
Altman, JK; Beauchamp, E; Eklund, EA; Goussetis, DJ; Kosciuczuk, EM; Platanias, LC; Wu, EJ	1
Aldoss, I; Douer, D; Mark, L; Mohrbacher, AM; Ramezani, L; Vrona, J; Weitz, I	1
Bi, L; Jiang, L; Lin, F; Ni, W; Tan, Y; Wang, F; Wu, J; Zhang, P	1
Altman, JK; Beauchamp, EM; Kosciuczuk, EM; Nanavati, D; O'Halloran, TV; Platanias, LC; Serrano, R; Swindell, EP; Viollet, B	1
Chen, X; Dong, K; He, T; Li, J; Lin, F; Long, M; Ouyang, Y; Wang, X; Wei, J; Weng, Y; Zhang, H	1
Aller, P; Boyano-Adánez, Mdel C; Calviño, E; Calvo, S; de Blas, E; Estañ, MC; Guillén-Guío, B; Rial, E	1
Bai, X; Guo, K; Guo, Z; He, H; He, X; Qiu, D; Wang, J; Weng, G; Xu, X; Ye, Y; Yi, W; Zhang, M; Zhou, R	1
Banfic, H; Dembitz, V; Lalic, H; Ostojic, A; Visnjic, D; Vrhovac, R	1
Brunetti, L; Di Raimondo, F; Falini, B; Gionfriddo, I; Martelli, MP; Mezzasoma, F; Milano, F; Mulas, F; Pacini, R; Pettirossi, V; Pierangeli, S; Rossi, R; Sportoletti, P; Tabarrini, A; Tiacci, E; Vetro, C	1
Ades, L; Bazarbachi, A; Berthier, C; Darwiche, N; Dassouki, Z; de Thé, H; Dombret, H; El Hajj, H; Fenaux, P; Hleihel, R; Legrand, O; Mohty, M; Raffoux, E; Sahin, U; Salameh, A; Tawil, N; Zibara, K	1
Chan, TS; Chau, D; Cheng, YY; Fong, B; Kwong, YL; Ng, K; Tam, S; Tse, E	1
Bhatnagar, V; Carter-Cooper, B; Emadi, A; Lapidus, RG; Levis, MJ; Sadowska, M; Sausville, EA; van der Merwe, I	1
Chen, Z; Chen, ZZ; Jiang, JP; Li, J; Lin, SY; Qian, WB; Shen, YY; Wang, B; Wu, LQ	1
Gu, H; Li, L; Ren, Y; Zhang, H; Zhang, L	1
Kolb, EA; Meshinchi, S	1
Huang, LB; Ke, ZY; Li, Y; Liu, XJ; Luo, XQ; Tan, HZ; Tang, YL; Wang, LN; Zhang, YC; Zhang, ZH	1
Ashton, JM; Becker, MW; Gasparetto, M; Humphries, KR; Jordan, CT; Khan, N; Minhajuddin, M; Myers, JR; Pei, S; Pollyea, DA; Smith, CA; Vasiliou, V	1
Roboz, GJ	1
Chen, KS; Chou, MC; Chu, SC; Hsiao, YC; Hsieh, YS; Kuo, DY; Lin, TH	1
Allen-Bard, S; Carlin, R; Christos, PJ; Curcio, T; Feldman, EJ; Mathew, S; Mazumdar, M; Provenzano, J; Ritchie, EK; Roboz, GJ; Samuel, M; Wittenberg, B	1
Au, WY; Fong, BM; Kwong, YL; Tam, S	1
Coe, E; Schimmer, AD	1
Haferlach, T	1
Petrie, K; Waxman, S; Zelent, A	1
Dong, D; Fei, J; Gu, J; Hu, H; Huang, K; Li, Y; Lin, C; Yao, J; Zhu, X	1
Canestraro, M; Cine, N; Galimberti, S; Guerrini, F; Metelli, MR; Nagy, B; Palumbo, GA; Petrini, M; Piaggi, S; Savli, H; Tibullo, D	1
Altman, JK; Glaser, H; Goussetis, DJ; McNeer, JL; Platanias, LC; Tallman, MS	1
Advani, A; Afable, M; Chan, J; Englehaupt, R; Erba, HP; Kalaycio, ME; Maciejewski, JP; Seel, S; Sekeres, MA; Sobecks, R	1
Andrews, C; Baer, MR; Barcos, M; Baumann, H; Block, AW; Ford, LA; Nowak, NJ; Sait, SN; Tighe, S; Wang, ES; Wetzler, M	1
Bowen, D; Burnett, AK; Cahalin, P; Craig, J; Hills, RK; Hunter, A; Kell, J; McMullin, MF; Milligan, D; Russell, N; Wheatley, K; Yin, J	1
Burnett, AK; Hills, RK	1
Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE	1
Abboud, CN; Cashen, AF; DiPersio, JF; Gao, F; Hassan, A; Klco, JM; Procknow, E; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P	1
Cao, L; Liu, L; Wang, Z; Xie, M; Yang, L; Yang, M; Yu, Y; Zhang, H; Zhao, M	1
Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ	1
Christos, PJ; Feldman, EJ; Gergis, U; Mayer, S; Ritchie, EK; Roboz, GJ; Scandura, JM; Wissa, U	1
Ding, Y; Fei, J; Li, Y; Zhang, Y; Zhu, X	1
Gabrilove, J; Jing, Y; Wang, R; Waxman, S; Xia, L	1
Chen, XL; Cong, WH; Guo, G; Li, H; Li, XX; Wang, R; Yu, XN	1
Chen, H; Liu, J; Liu, L; Liu, M; Shi, B; Ye, L; Yu, L; Zhang, Y	1
Altman, JK; Galvin, JP; Goussetis, DJ; Platanias, LC; Sassano, A; Szilard, A; Vakana, E	1
Udvardy, M	1
Takeshita, A	1
Meng, R; Yang, BF; Zhao, DY; Zhou, J	1
Hahm, ER; Han, SS; Jung, CW; Kim, K; Kim, WS; Kimler, BF; Lee, JH; Lee, MH; Lee, SJ; Park, CH; Park, HK; Park, K; Park, S; Riordan, HD; Riordan, NH; Surh, YJ; Yang, JH; Yoon, SS	1
Hahm, ER; Han, SS; Jung, CW; Kim, J; Kim, K; Kim, WS; Kimler, BF; Lee, JH; Lee, SH; Lee, SJ; Park, CH; Park, K; Park, S; Yoon, SS	1
Civallero, M; Cosenza, M; Marcheselli, R; Pozzi, S; Sacchi, S	1
Bonati, A; Costanzo, A; Levrero, M; Lo-Coco, F; Lunghi, P; Mazzera, L; Noguera, N; Salvatore, L; Tabilio, A	1
Meng, L; Meng, R; Sui, XH; Yang, BF; Zhou, J	1
Abe, S; Harigae, H; Imaizumi, M; Ishikawa, I; Kaku, M; Sasaki, T; Takahashi, S; Yokoyama, H	1
Baer, MR; Baumann, H; Brady, MT; Cheng, Y; Cowell, JK; Donohue, KA; Kunapuli, P; Li, ZR; McDonald, AA; Mortazavi, A; O'Loughlin, KL; Tracy, E; Wallace, PK; Wetzler, M	1
Altman, JK; Glaser, H; Hay, N; Jordan, A; Katsoulidis, E; Kroczynska, B; Platanias, LC; Redig, AJ; Sassano, A; Tallman, MS; Yoon, P	1
Craig, CM; Schiller, GJ	1
Bengtzen, S; Christensson, B; Lehmann, S; Paul, A; Paul, C	1

Reviews

11 review(s) available for arsenic trioxide and Leukemia, Myeloid, Acute

Article	Year
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement. Nagoya journal of medical science, 2020, Volume: 82, Issue:2 Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines	2020
Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. American journal of hematology, 2021, 06-01, Volume: 96, Issue:6 Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Antineoplastic Agents; Arsenic Trioxide; Cell Differentiation; Clinical Trials as Topic; Cytokine Release Syndrome; Edema; Enzyme Inhibitors; Epigenesis, Genetic; Fever; fms-Like Tyrosine Kinase 3; Humans; Hypotension; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myelopoiesis; Neoplasm Proteins; Pleural Effusion; Respiration Disorders; Tretinoin	2021
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer, 2021, 04-15, Volume: 127, Issue:8 Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine	2021
Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies. Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Clinical Trials as Topic; Down Syndrome; Epigenesis, Genetic; GATA1 Transcription Factor; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Medical Oncology; Molecular Medicine; Mutation; Oxides; ras Proteins; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Tretinoin	2015
Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia. Seminars in hematology, 2008, Volume: 45, Issue:3 Suppl 2 Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Treatment Outcome	2008
Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematology. American Society of Hematology. Education Program, 2008 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; Chromosome Aberrations; Genetic Markers; Humans; Karyotyping; Leukemia, Myeloid, Acute; Models, Genetic; Mutation; Oxides; Proto-Oncogene Proteins c-kit; Transcription, Genetic; Tretinoin	2008
Differentiation therapy of acute myeloid leukemia: past, present and future. Current opinion in hematology, 2009, Volume: 16, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Sensitivity and Specificity; Tretinoin	2009
[Current treatment of acute myeloid leukaemia in adults]. Orvosi hetilap, 2012, Feb-19, Volume: 153, Issue:7 Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin	2012
[Expanding possibilities, strategic considerations, and novel methods in the diagnosis and chemotherapy of adult acute myeloid leukemia]. Orvosi hetilap, 2003, Sep-07, Volume: 144, Issue:36 Topics: Adult; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oxides; Palliative Care; Prognosis; Remission Induction; Tretinoin	2003
[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2003, Volume: 44, Issue:12 Topics: Alkyl and Aryl Transferases; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cyclosporine; Cytarabine; Daunorubicin; Drug Design; Farnesyltranstransferase; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Nucleosides; Oxides; Prognosis; Radioisotopes; Remission Induction; Tetrahydronaphthalenes; Topoisomerase Inhibitors; Tretinoin; Verapamil	2003
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. Blood reviews, 2008, Volume: 22, Issue:4 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides	2008

Trials

9 trial(s) available for arsenic trioxide and Leukemia, Myeloid, Acute

Article	Year
Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia. Annals of hematology, 2014, Volume: 93, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Treatment Outcome	2014
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer, 2008, Nov-01, Volume: 113, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Remission Induction; Survival Rate	2008
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer, 2011, Mar-15, Volume: 117, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Oxides; Salvage Therapy; Treatment Outcome	2011
Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. Cancer, 2011, Nov-01, Volume: 117, Issue:21 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Down-Regulation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; STAT3 Transcription Factor	2011
The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia, 2011, Volume: 25, Issue:7 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Comorbidity; Cytarabine; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Diseases; Heart Diseases; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome	2011
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer investigation, 2011, Volume: 29, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib	2011
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. American journal of hematology, 2011, Volume: 86, Issue:9 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Azacitidine; Bone Marrow; Bone Marrow Cells; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Young Adult	2011
Effects of arsenic trioxide administration styles on leukocytosis. Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2006, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Humans; Infusions, Intravenous; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides	2006
Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication. International journal of hematology, 2006, Volume: 84, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mitogen-Activated Protein Kinase Kinases; Mutation; Oxides; Signal Transduction; Tumor Cells, Cultured; Tyrphostins	2006

Other Studies

72 other study(ies) available for arsenic trioxide and Leukemia, Myeloid, Acute

Article	Year
A Novel NUP98/RARG Gene Fusion in Pediatric Acute Myeloid Leukemia Resembling Acute Promyelocytic Leukemia. Journal of pediatric hematology/oncology, 2022, 04-01, Volume: 44, Issue:3 Topics: Adult; Arsenic Trioxide; Child; Chromosome Aberrations; Gene Fusion; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Nuclear Pore Complex Proteins	2022
Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation. International journal of molecular sciences, 2022, Jun-12, Volume: 23, Issue:12 Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2; Oxides; Reactive Oxygen Species; Recurrence; Sulfonamides	2022
p53 as a unique target of action of cisplatin in acute leukaemia cells. Journal of cellular and molecular medicine, 2022, Volume: 26, Issue:17 Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cisplatin; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Ovarian Neoplasms; Tumor Suppressor Protein p53	2022
[Acute Myeloid Leukemia - Update 2022]. Deutsche medizinische Wochenschrift (1946), 2022, Volume: 147, Issue:17 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Tretinoin	2022
[Effect of Dihydroartemisinin and Arsenic Trioxide on Apoptosis of Acute Myeloid Leukemia Cells]. Zhongguo shi yan xue ye xue za zhi, 2022, Volume: 30, Issue:5 Topics: Apoptosis; Arsenic Trioxide; Artemisinins; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Poly(ADP-ribose) Polymerase Inhibitors; Reactive Oxygen Species	2022
CPSF6-RARG-positive acute myeloid leukaemia resembles acute promyelocytic leukaemia but is insensitive to retinoic acid and arsenic trioxide. Pathology, 2023, Volume: 55, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Retinoic Acid Receptor gamma; Tretinoin	2023
Curcumin combined with arsenic trioxide in the treatment of acute myeloid leukemia: network pharmacology analysis and experimental validation. Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:1 Topics: Animals; Arsenic Trioxide; Curcumin; Drugs, Chinese Herbal; Leukemia, Myeloid, Acute; Mice; Network Pharmacology; Tumor Suppressor Protein p53	2023
A global study for acute myeloid leukemia with RARG rearrangement. Blood advances, 2023, 07-11, Volume: 7, Issue:13 Topics: Arsenic Trioxide; HLA-DR Antigens; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Tretinoin	2023
Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines. Leukemia research, 2023, Volume: 128 Topics: Antineoplastic Agents; Arsenic Trioxide; Cell Line, Tumor; Cytarabine; Humans; Leukemia, Myeloid, Acute; Phenotype	2023
Report of PRPF19 as a novel partner of RARG and the recurrence of interposition-type fusion in variant acute promyelocytic leukemia. Hematological oncology, 2023, Volume: 41, Issue:4 Topics: Arsenic Trioxide; DNA Repair Enzymes; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Receptors, Retinoic Acid; RNA Splicing Factors; Tretinoin	2023
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. Leukemia, 2020, Volume: 34, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; International Cooperation; Leukemia, Myeloid, Acute; Male; Remission Induction; Treatment Outcome	2020
Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD. Leukemia & lymphoma, 2020, Volume: 61, Issue:11 Topics: Arsenic Trioxide; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Prognosis; Tretinoin	2020
Effects of different autophagy inhibitors on sensitizing KG-1 and HL-60 leukemia cells to chemotherapy. IUBMB life, 2021, Volume: 73, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Autophagy; Cell Proliferation; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Tretinoin; Tumor Cells, Cultured	2021
Toll-like receptor 4 signaling pathway is correlated with pathophysiological characteristics of AML patients and its inhibition using TAK-242 suppresses AML cell proliferation. International immunopharmacology, 2021, Volume: 90 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cell Cycle; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Signal Transduction; Sulfonamides; Toll-Like Receptor 4; U937 Cells; Young Adult	2021
MiR-451 Promotes Cell Apoptosis and Inhibits Autophagy in Pediatric Acute Myeloid Leukemia by Targeting HMGB1. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2021, Volume: 40, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Autophagy; Child; HL-60 Cells; HMGB1 Protein; Humans; Leukemia, Myeloid, Acute; MicroRNAs; THP-1 Cells	2021
Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia. Cancer medicine, 2021, Volume: 10, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Bone Marrow; Child; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Disseminated Intravascular Coagulation; DNA Helicases; DNA-Binding Proteins; Female; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nuclear Proteins; Oncogene Proteins, Fusion; Prognosis; Promyelocytic Leukemia Zinc Finger Protein; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin	2021
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro. Oncotarget, 2017, May-16, Volume: 8, Issue:20 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oxides; Reactive Oxygen Species; Survival Analysis; Tumor Cells, Cultured	2017
Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells Asian Pacific journal of cancer prevention : APJCP, 2018, Apr-27, Volume: 19, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Oxides; Thalidomide; U937 Cells; Vascular Endothelial Growth Factors	2018
[Effects of Arsenic Trioxide on Cdc20 and Mad2 in Acute Myeloid Leukemia HL-60 Cell Line]. Zhongguo shi yan xue ye xue za zhi, 2018, Volume: 26, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cdc20 Proteins; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides	2018
Blockade of JAK2/STAT3 intensifies the anti-tumor activity of arsenic trioxide in acute myeloid leukemia cells: Novel synergistic mechanism via the mediation of reactive oxygen species. European journal of pharmacology, 2018, Sep-05, Volume: 834 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Line, Tumor; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Nitriles; Oxidative Stress; Pyrazoles; Pyrimidines; Reactive Oxygen Species; S Phase Cell Cycle Checkpoints; Signal Transduction; STAT3 Transcription Factor	2018
The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells. Haematologica, 2019, Volume: 104, Issue:5 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Autophagy; Basigin; Cell Proliferation; Cytarabine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Glycoproteins; Humans; Leukemia, Myeloid, Acute; Phenols; Prognosis; Signal Transduction; Small Molecule Libraries; Survival Rate; Tumor Cells, Cultured	2019
The effect of simultaneous administration of arsenic trioxide and microvesicles derived from human bone marrow mesenchymal stem cells on cell proliferation and apoptosis of acute myeloid leukemia cell line. Artificial cells, nanomedicine, and biotechnology, 2018, Volume: 46, Issue:sup3 Topics: Apoptosis; Arsenic Trioxide; Cell Line, Tumor; Cell Proliferation; Cell-Derived Microparticles; Humans; Leukemia, Myeloid, Acute; Mesenchymal Stem Cells	2018
Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells. Experimental cell research, 2019, 03-15, Volume: 376, Issue:2 Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cell Adhesion; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Mice, SCID; Middle Aged; Xenograft Model Antitumor Assays; Young Adult	2019
Acute myeloid leukemia in an 86-year-old man with AML1/ETO treated with Homoharringtonine and Arsenic Trioxide: A case report. Medicine, 2019, Volume: 98, Issue:13 Topics: Aged, 80 and over; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Differentiation; Core Binding Factor Alpha 2 Subunit; Drug Therapy, Combination; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Oncogene Proteins, Fusion; RUNX1 Translocation Partner 1 Protein	2019
MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide. Oncology research, 2019, Sep-23, Volume: 27, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Line, Tumor; HL-60 Cells; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; MicroRNAs; Tumor Suppressor Protein p53; Up-Regulation	2019
A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide. British journal of cancer, 2019, Volume: 120, Issue:11 Topics: Aged; Arsenic Trioxide; Drug Resistance, Neoplasm; Gene Fusion; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Nuclear Proteins; Nucleophosmin; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma; Tretinoin	2019
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell research, 2019, Volume: 29, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease Models, Animal; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Neoplasms, Experimental; Tretinoin; Tumor Cells, Cultured; U937 Cells	2019
Combination therapy with 5-amino-4-imidazolecarboxamide riboside and arsenic trioxide in acute myeloid leukemia cells involving AMPK/TSC2/mTOR pathway. Die Pharmazie, 2013, Volume: 68, Issue:2 Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; HL-60 Cells; Humans; Hypoglycemic Agents; Leukemia, Myeloid, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Ribonucleotides; Signal Transduction; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins	2013
Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function. Leukemia research, 2013, Volume: 37, Issue:7 Topics: Aminosalicylic Acids; Antigen-Presenting Cells; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzenesulfonates; Blast Crisis; Blotting, Western; Dendritic Cells; Down-Regulation; Endocytosis; Enzyme-Linked Immunosorbent Assay; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Lymphocyte Activation; Oxides; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; T-Lymphocytes; Tumor Cells, Cultured	2013
Low-dose 1,25-dihydroxyvitamin D(3) combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis. Oncology reports, 2013, Volume: 30, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Bone Density Conservation Agents; Calcitriol; Caspase 3; Cell Line, Tumor; Cell Survival; Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+); HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Oxides; Proto-Oncogene Proteins c-bcl-2	2013
[Effect of TAK1 gene silencing on the apoptosis of Kasumi-1 cells induced by arsenic trioxide]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:5 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid, Acute; MAP Kinase Kinase Kinases; Oxides; RNA Interference; RNA, Small Interfering; Signal Transduction	2013
Growth and differentiation effects of Homer3 on a leukemia cell line. Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Carrier Proteins; Cell Cycle; Cell Differentiation; Cell Proliferation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Homer Scaffolding Proteins; Humans; Leukemia, Myeloid, Acute; Oxides; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured	2013
Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia, 2013, Volume: 27, Issue:10 Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Nucleolus; Cell Proliferation; Cysteine; Cytosol; Drug Resistance, Neoplasm; Flow Cytometry; Free Radical Scavengers; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Oxides; Pyrazines; Reactive Oxygen Species; Tryptophan; Tumor Cells, Cultured	2013
Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3. Neoplasma, 2013, Volume: 60, Issue:6 Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Oxides; Prognosis; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tandem Repeat Sequences; Tretinoin; Young Adult	2013
BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine. BMC cancer, 2014, Jan-15, Volume: 14 Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; Buthionine Sulfoximine; Drug Combinations; Gene Knockdown Techniques; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Oxidative Stress; Oxides; Phosphorylation; Proto-Oncogene Proteins	2014
Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors. Cancer biology & therapy, 2014, Volume: 15, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Drug Synergism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Oxides; Resveratrol; Stilbenes	2014
Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide. International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Survival; Disulfides; Flow Cytometry; HL-60 Cells; Humans; Imidazoles; Leukemia, Myeloid, Acute; Oxides; Thioredoxins	2014
Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors. Molecular cancer therapeutics, 2015, Volume: 14, Issue:1 Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Mice; Oxides; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2015
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cellular signalling, 2015, Volume: 27, Issue:3 Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; B7-H1 Antigen; Base Sequence; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Interferon-gamma; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Oligonucleotides, Antisense; Oxides; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Sequence Alignment; Up-Regulation	2015
Apoptotic efficacy of etomoxir in human acute myeloid leukemia cells. Cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activities. PloS one, 2014, Volume: 9, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Deoxyglucose; Epoxy Compounds; Glycolysis; Humans; Indazoles; Leukemia, Myeloid, Acute; Oxidative Stress; Oxides; Protein Kinases	2014
Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis. Leukemia & lymphoma, 2015, Volume: 56, Issue:11 Topics: Aclarubicin; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides	2015
The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation. International journal of hematology, 2015, Volume: 102, Issue:1 Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Drug Synergism; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinases; Oxides; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Translocation, Genetic	2015
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood, 2015, May-28, Volume: 125, Issue:22 Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Mutant Proteins; Mutation; Nuclear Proteins; Nucleophosmin; Oncogene Proteins; Oxides; Tretinoin; Tumor Cells, Cultured; U937 Cells; Xenograft Model Antitumor Assays	2015
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood, 2015, May-28, Volume: 125, Issue:22 Topics: Aged; Aged, 80 and over; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Myeloid, Acute; Mutant Proteins; Mutation; Nuclear Proteins; Nucleophosmin; Oxides; Proteolysis; Tretinoin; Tumor Cells, Cultured	2015
Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9. Journal of hematology & oncology, 2015, May-08, Volume: 8 Topics: Antineoplastic Combined Chemotherapy Protocols; Aquaporins; Arsenic Trioxide; Arsenicals; Azacitidine; Blotting, Western; Cell Line, Tumor; Cells, Cultured; Drug Synergism; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Oxides; Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Up-Regulation	2015
Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia. Leukemia research, 2015, Volume: 39, Issue:7 Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dichloroacetic Acid; Humans; Leukemia, Myeloid, Acute; Oxidative Stress; Oxides	2015
Pure total flavonoids from Citrus paradisi Macfadyen act synergistically with arsenic trioxide in inducing apoptosis of Kasumi-1 leukemia cells in vitro. Journal of Zhejiang University. Science. B, 2015, Volume: 16, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Flavonoids; Humans; Leukemia, Myeloid, Acute; Oxides; Plant Extracts; Treatment Outcome	2015
EZH2 mediates ATO-induced apoptosis in acute myeloid leukemia cell lines through the Wnt signaling pathway. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression; Gene Knockdown Techniques; Glycogen Synthase Kinase 3 beta; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides; Phosphorylation; Wnt Signaling Pathway	2016
Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways. Leukemia & lymphoma, 2017, Volume: 58, Issue:10 Topics: Apoptosis; Arsenic Trioxide; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Signal Transduction; Tretinoin	2017
Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1. Haematologica, 2017, Volume: 102, Issue:6 Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Arsenic Trioxide; Arsenicals; Cells, Cultured; Cyclophosphamide; Drug Therapy, Combination; Heterografts; Humans; Leukemia, Myeloid, Acute; Mice; Molecular Targeted Therapy; Oxides; Retinal Dehydrogenase	2017
Tannic acid-induced apoptosis and -enhanced sensitivity to arsenic trioxide in human leukemia HL-60 cells. Leukemia research, 2009, Volume: 33, Issue:2 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Drug Synergism; HL-60 Cells; Humans; Kinetics; Leukemia, Myeloid, Acute; Mitochondria; Oxides; Superoxide Dismutase; Tannins	2009
Oral arsenic treatment of leukemia and the risk of porphyria. Leukemia research, 2009, Volume: 33, Issue:4 Topics: Administration, Oral; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Oxides; Porphyrias; Porphyrins	2009
Catalase activity and arsenic sensitivity in acute leukemia. Leukemia & lymphoma, 2008, Volume: 49, Issue:10 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Line, Tumor; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured	2008
miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Proliferation; Flow Cytometry; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; MicroRNAs; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured	2011
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer genetics and cytogenetics, 2010, Volume: 199, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blast Crisis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 8; Cell Cycle; Cell Proliferation; Drug Synergism; Gene Expression Profiling; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; NF-kappa B; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand	2010
Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. The Journal of biological chemistry, 2010, Sep-24, Volume: 285, Issue:39 Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Autophagy; Autophagy-Related Protein 7; Beclin-1; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Knockout; Microtubule-Associated Proteins; Oxides; U937 Cells; Ubiquitin-Activating Enzymes	2010
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. Blood, 2011, Sep-01, Volume: 118, Issue:9 Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom	2011
S100A8-targeting siRNA enhances arsenic trioxide-induced myeloid leukemia cell death by down-regulating autophagy. International journal of molecular medicine, 2012, Volume: 29, Issue:1 Topics: Active Transport, Cell Nucleus; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Autophagy; Beclin-1; Calgranulin A; Down-Regulation; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Membrane Proteins; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; RNA, Small Interfering; Transfection; Tumor Cells, Cultured	2012
Are low-intensity induction strategies better for older patients with acute myeloid leukemia? Leukemia research, 2012, Volume: 36, Issue:4 Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Quinolones; Remission Induction; Retrospective Studies; Treatment Outcome	2012
Targeted inhibition of VEGF-modulated survival and arsenic sensitivity in acute myeloid leukemia (AML). Hematology (Amsterdam, Netherlands), 2012, Volume: 17, Issue:3 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cell Survival; Drug Synergism; Gene Silencing; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Oligonucleotides, Antisense; Oxides; Primary Cell Culture; Transfection; Trypan Blue; Vascular Endothelial Growth Factor A	2012
Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia, 2013, Volume: 27, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Down-Regulation; Enzyme Activation; Flow Cytometry; Glutathione; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Leukemia, Myeloid, Acute; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; RNA, Small Interfering; Tumor Cells, Cultured	2013
Synergism between carnosic acid and arsenic trioxide on induction of acute myeloid leukemia cell apoptosis is associated with modulation of PTEN/Akt signaling pathway. Chinese journal of integrative medicine, 2012, Volume: 18, Issue:12 Topics: Abietanes; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Blotting, Western; Cell Cycle; DNA Primers; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides; Plant Extracts; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction	2012
A case report of acute myeloid leukemia after liver transplantation. Acta haematologica, 2013, Volume: 129, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Cytarabine; Daunorubicin; Hepatitis B; Humans; Leukemia, Myeloid, Acute; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mitoxantrone; Oxides; Tretinoin	2013
Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses. Cancer biology & therapy, 2013, Volume: 14, Issue:5 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Electrophoresis, Polyacrylamide Gel; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Oxides; Phosphorylation; Ribosomal Protein S6 Kinases, 90-kDa; U937 Cells	2013
A case of M2a with complex chromosome aberrations obtained complete remission through modified As2O3 medication. Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2004, Volume: 19, Issue:2 Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Chromosome Aberrations; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Oxides; Remission Induction	2004
L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. Journal of cellular biochemistry, 2004, Oct-01, Volume: 93, Issue:2 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cyclooxygenase 2; DNA; Down-Regulation; Electrophoretic Mobility Shift Assay; Glutathione; HL-60 Cells; Humans; Hydrogen Peroxide; Isoenzymes; Leukemia, Myeloid, Acute; Membrane Proteins; NF-kappa B; Oxides; Prostaglandin-Endoperoxide Synthases; Protein Subunits; Superoxides; Tosylphenylalanyl Chloromethyl Ketone; Transcription Factor RelA	2004
Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. Journal of cellular biochemistry, 2005, Mar-01, Volume: 94, Issue:4 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cyclooxygenase 2; DNA; Enzyme Activation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione; HL-60 Cells; Humans; Hydrogen Peroxide; I-kappa B Kinase; Leukemia, Myeloid, Acute; Membrane Proteins; NF-kappa B; Oxides; Prostaglandin-Endoperoxide Synthases; Protein Binding; Protein Serine-Threonine Kinases; Protein Subunits; Protein Transport	2005
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts. Leukemia & lymphoma, 2005, Volume: 46, Issue:2 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Bromodeoxyuridine; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Interactions; Humans; Ki-67 Antigen; Kinetics; Leukemia, Myeloid, Acute; Oxides; S Phase; Tretinoin; Tumor Cells, Cultured	2005
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood, 2006, Jun-01, Volume: 107, Issue:11 Topics: Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Female; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid, Acute; Male; MAP Kinase Kinase 1; Middle Aged; Nuclear Proteins; Oxides; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2006
Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Nov-15, Volume: 12, Issue:22 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carrier Proteins; Cell Cycle; Cell Proliferation; DNA-Binding Proteins; Humans; Leukemia, Myeloid, Acute; Oxides; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Signal Transduction; STAT Transcription Factors; STAT3 Transcription Factor; Transcription Factors; Transfection; Tumor Cells, Cultured	2006
Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. The Journal of biological chemistry, 2008, Jan-25, Volume: 283, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Eukaryotic Initiation Factors; Gene Deletion; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Oxides; Protein Kinases; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; U937 Cells	2008
Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance. European journal of haematology, 2001, Volume: 66, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance; Drug Resistance, Multiple; Female; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Transfection; Tumor Cells, Cultured	2001